Plasma MicroRNA, a Potential Biomarker for Acute Rejection After Liver Transplantation
Plasma MicroRNA, a Potential Biomarker for Acute Rejection After Liver Transplantation
复制标题
DOI：
10.1097/tp.0b013e31828618d8
复制
发表时间：
2013-04-27
期刊：
影响因子：
6.2
通讯作者：
Zhou, Jian
中科院分区：
文献类型：
--
作者：
Hu, Jie;Wang, Zheng;Zhou, Jian
背景器官移植的急性排斥反应（AR）是一种危及生命的并发症。目前，适合临床应用的诊断性生物标志物很少。我们的目的是确定血浆microRNA作为AR生物标志物的潜力。利用大鼠原位肝移植模型和微阵列技术，我们比较了AR大鼠和对照组血浆和移植物中microRNA的谱和水平的差异。选择AR相关的血浆microRNA，并使用实时定量聚合酶链反应进行验证。使用来自有或没有他克莫司治疗的AR大鼠的血浆进行microRNA动态监测。为明确AR相关microRNA的来源，建立大鼠药物性肝损伤模型，应用原位杂交技术检测并定位AR相关microRNA。我们发现，当AR发生时，血浆miR-122、miR-192和miR-146 a显著上调（倍数变化>2; P
Background. Acute rejection (AR) of an organ transplant is a life-threatening complication. Currently, there are few diagnostic biomarkers suitable for clinical application. We aim to determine the potential of plasma microRNAs as biomarkers for AR.Methods. Using rat orthotopic liver transplantation model and microarrays, we compared the difference in the spectrum and levels of microRNAs in both plasma and grafts between AR rats and control. AR-related plasma microRNAs were selected and validated using real-time quantification polymerase chain reaction. Plasma from AR rats with or without tacrolimus treatment was used for microRNA dynamic monitoring. To clarify the origin of AR-related plasma microRNAs, drug-induced liver damage rat model were performed and in situ hybridization was used to detect and localize the specific microRNA in allografts.Results. We found that plasma miR-122, miR-192, and miR-146a was significantly up-regulated when AR occur (fold change>2; P